A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapyValentina Guarneri, PierFranco Conte, Antonino Maiorana et al.|Annals of Oncology|2009Cited by 81
Preoperative Chemotherapy plus Lapatinib or Trastuzumab or Both in HER2-Positive Operable Breast Cancer (CHERLOB Trial)Valentina Guarneri, PierFranco Conte, Antonio Frassoldati et al.|Clinical Breast Cancer|2008Cited by 30
Primary systemic therapy for operable breast cancer: A review of clinical trials and perspectivesValentina Guarneri, PierFranco Conte, Francesca Borghi et al.|Cancer Letters|2006Cited by 27
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/− gefitinib with biomarker evaluation in operable breast cancerValentina Guarneri, PierFranco Conte, Antonio Frassoldati et al.|Breast Cancer Research and Treatment|2007Cited by 21
Letrozole Versus Letrozole plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized, Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB)Antonio Frassoldati, PierFranco Conte, Valentina Guarneri et al.|Clinical Breast Cancer|2008Cited by 14